Gastric body cholinergic contractile signal transduction in M₂ and M₃ receptor knockout mice

Abstract

Although most smooth muscles express a greater density of M₂ than M₃ muscarinic receptors, based on the potency of subtype selective muscarinic receptor antagonists, the M₃ subtype predominantly mediates contraction. The effect of inhibitors of putative contractile signal transduction pathway enzymes on carbachol-induced contractions was determined in wild-type (WT) mice and mice lacking either the M₂ (M₂KO) or the M₃ (M₃KO) receptor subtype. Contractile responses to KCl, then increasing carbachol concentrations in the presence and absence of enzyme inhibitors was determined. The KCl-induced contraction was not different between strains. The carbachol response was unaffected in the M₂KO strain but decreased 42% in M₃KO mice (p < 0.01). Darifenacin potency was high in both WT and M₂KO strains, indicating M₃-mediated contractions, and low in the M₃KO strain, suggesting M₂-mediated contractions. The phosphatidyl inositol-specific phospholipase C (Pi-PLC) inhibitor ET-18-OCH₃ had no effect. Inhibition of phosphatidyl choline-specific phospholipase C (PC-PLC) and sphingomyelin synthase with D609 decreased maximal contraction in all strains. M₃-mediated contractions in the M₂KO strain were decreased 54% by the protein kinase C (PKC) inhibitor chelerythrine. M₂-mediated contractions in the M₃KO and WT strains were decreased by the Rho kinase (ROCK) inhibitor Y27632 as well as the ROCK, PKA and PKG inhibitor H89. The M₃ subtype activates PKC and either PC-PLC or sphingomyelin synthase, while the M₂ subtype activates ROCK and either PC-PLC or sphingomyelin synthase. These studies suggest that multiple parallel pathways mediate cholinergic contractions in stomach body smooth muscle.

• Muscarinic receptors
• phospholipases
• rho kinase
• signal transduction
• smooth muscle
• sphingomyelin synthase